Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068580551> ?p ?o ?g. }
- W2068580551 endingPage "383" @default.
- W2068580551 startingPage "377" @default.
- W2068580551 abstract "The purpose of the study was to analyze the results with radiotherapy alone in a select group of asymptomatic adults with nonbulky, early-stage lymphocyte-predominant Hodgkin's disease.Between 1963 and 1995, 36 patients with nonbulky stage IA (N = 27) or IIA (N = 9) supradiaphragmatic (N = 27) or subdiaphragmatic (N = 9) lymphocyte-predominant Hodgkin's disease were treated with radiotherapy alone. Eleven of the patients underwent laparotomy. Limited-field radiotherapy involving only one side of the diaphragm and extended-field radiotherapy encompassing both sides of the diaphragm were used in 28 and 8 cases, respectively. Median dose to involved areas was 40.0 Gy given daily in 20 2.0-Gy fractions. Salvage treatmentconsisted of MOPP (mechlorethamine, vincristine, prednisone, procarbazine), CVPP/ABDIC (cyclophosphamide, vinblastine, procarbazine and prednisone/doxorubicin, bleomycin, dacarbazine, lomustine, and prednisone), or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy and/or involved-field radiotherapy.Median follow-up was 8.8 years (range, 3.0-34.4 years). None of the 15 patients with supradiaphragmatic disease who received limited-field radiotherapy to regions that did not include the mediastinal or hilar nodes subsequently experienced relapse there. Only one of 20 patients who received supradiaphragmatic limited-field radiotherapy alone experienced relapse in the paraaortic nodes or spleen. The 5-year relapse-free and overall survival rates for the 20 patients with stage IA lymphocyte-predominant Hodgkin's disease treated with involved-field or regional radiotherapy were 95% and 100%, respectively. There were no cases of severe or life-threatening cardiac toxicity. No solid tumors have been observed in-field in patients treated with limited-field radiotherapy, even though they have been followed up longer than those treated with extended-field radiotherapy (median follow-up, 11.6 vs 5.5 years); two solid tumors have developed in-field in patients who received extended-field radiotherapy.Involved-field or regional radiotherapy alone may be adequate in stage IA lymphocyte-predominant Hodgkin's disease patients. Longer follow-up will help to more clearly define the risks of cardiac toxicity and solid tumors that result from involved-field or regional radiotherapy, which appear to be low based on follow-up to date." @default.
- W2068580551 created "2016-06-24" @default.
- W2068580551 creator A5006742031 @default.
- W2068580551 creator A5028677309 @default.
- W2068580551 creator A5034765756 @default.
- W2068580551 creator A5040275365 @default.
- W2068580551 creator A5059988668 @default.
- W2068580551 creator A5060386553 @default.
- W2068580551 creator A5066313849 @default.
- W2068580551 creator A5068152076 @default.
- W2068580551 creator A5070451207 @default.
- W2068580551 creator A5085488112 @default.
- W2068580551 date "2002-09-01" @default.
- W2068580551 modified "2023-09-26" @default.
- W2068580551 title "Radiotherapy Alone for Lymphocyte-Predominant Hodgkin??s Disease" @default.
- W2068580551 cites W1536128075 @default.
- W2068580551 cites W1788295040 @default.
- W2068580551 cites W1819862099 @default.
- W2068580551 cites W1890322031 @default.
- W2068580551 cites W1939504905 @default.
- W2068580551 cites W1945262124 @default.
- W2068580551 cites W1973397914 @default.
- W2068580551 cites W2003385864 @default.
- W2068580551 cites W2016886789 @default.
- W2068580551 cites W2032975907 @default.
- W2068580551 cites W2038252730 @default.
- W2068580551 cites W2047853141 @default.
- W2068580551 cites W2067571463 @default.
- W2068580551 cites W2077791684 @default.
- W2068580551 cites W2086951200 @default.
- W2068580551 cites W2091291718 @default.
- W2068580551 cites W2107202569 @default.
- W2068580551 cites W2120763744 @default.
- W2068580551 cites W2135361829 @default.
- W2068580551 cites W2150373911 @default.
- W2068580551 cites W2162084836 @default.
- W2068580551 cites W2166104105 @default.
- W2068580551 cites W2213506447 @default.
- W2068580551 cites W2257019489 @default.
- W2068580551 cites W2262106173 @default.
- W2068580551 cites W2263695274 @default.
- W2068580551 cites W2272862175 @default.
- W2068580551 cites W2340481879 @default.
- W2068580551 cites W4293241248 @default.
- W2068580551 doi "https://doi.org/10.1097/00130404-200209000-00008" @default.
- W2068580551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12416895" @default.
- W2068580551 hasPublicationYear "2002" @default.
- W2068580551 type Work @default.
- W2068580551 sameAs 2068580551 @default.
- W2068580551 citedByCount "63" @default.
- W2068580551 countsByYear W20685805512012 @default.
- W2068580551 countsByYear W20685805512013 @default.
- W2068580551 countsByYear W20685805512014 @default.
- W2068580551 countsByYear W20685805512015 @default.
- W2068580551 countsByYear W20685805512016 @default.
- W2068580551 countsByYear W20685805512017 @default.
- W2068580551 countsByYear W20685805512018 @default.
- W2068580551 countsByYear W20685805512020 @default.
- W2068580551 countsByYear W20685805512022 @default.
- W2068580551 crossrefType "journal-article" @default.
- W2068580551 hasAuthorship W2068580551A5006742031 @default.
- W2068580551 hasAuthorship W2068580551A5028677309 @default.
- W2068580551 hasAuthorship W2068580551A5034765756 @default.
- W2068580551 hasAuthorship W2068580551A5040275365 @default.
- W2068580551 hasAuthorship W2068580551A5059988668 @default.
- W2068580551 hasAuthorship W2068580551A5060386553 @default.
- W2068580551 hasAuthorship W2068580551A5066313849 @default.
- W2068580551 hasAuthorship W2068580551A5068152076 @default.
- W2068580551 hasAuthorship W2068580551A5070451207 @default.
- W2068580551 hasAuthorship W2068580551A5085488112 @default.
- W2068580551 hasConcept C121608353 @default.
- W2068580551 hasConcept C126322002 @default.
- W2068580551 hasConcept C141071460 @default.
- W2068580551 hasConcept C143998085 @default.
- W2068580551 hasConcept C2776232574 @default.
- W2068580551 hasConcept C2776305933 @default.
- W2068580551 hasConcept C2776694085 @default.
- W2068580551 hasConcept C2776755627 @default.
- W2068580551 hasConcept C2777132456 @default.
- W2068580551 hasConcept C2778720950 @default.
- W2068580551 hasConcept C2779112685 @default.
- W2068580551 hasConcept C2779338263 @default.
- W2068580551 hasConcept C2779429289 @default.
- W2068580551 hasConcept C2780427987 @default.
- W2068580551 hasConcept C2780430958 @default.
- W2068580551 hasConcept C2780964509 @default.
- W2068580551 hasConcept C2781100745 @default.
- W2068580551 hasConcept C2992779791 @default.
- W2068580551 hasConcept C509974204 @default.
- W2068580551 hasConcept C71924100 @default.
- W2068580551 hasConcept C90924648 @default.
- W2068580551 hasConceptScore W2068580551C121608353 @default.
- W2068580551 hasConceptScore W2068580551C126322002 @default.
- W2068580551 hasConceptScore W2068580551C141071460 @default.
- W2068580551 hasConceptScore W2068580551C143998085 @default.
- W2068580551 hasConceptScore W2068580551C2776232574 @default.
- W2068580551 hasConceptScore W2068580551C2776305933 @default.
- W2068580551 hasConceptScore W2068580551C2776694085 @default.